Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

698
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
698
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.1K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

653
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
653
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

957
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
957
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

651
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
651

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy.

Transplant infectious disease : an official journal of the Transplantation Society·2024
Same author

Novel indications for referral and care for simultaneous liver kidney transplant recipients.

Current opinion in nephrology and hypertension·2024
Same author

A multicenter prospective study to define the natural history of BK viral infections in kidney transplantation.

Transplant infectious disease : an official journal of the Transplantation Society·2024
Same author

Understanding Delayed Graft Function to Improve Organ Utilization and Patient Outcomes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2023
Same author

Survey of Salary and Job Satisfaction of Transplant Nephrologists in the United States.

Clinical journal of the American Society of Nephrology : CJASN·2022
Same author

Existing Transplant Nephrology Compensation Models and Opportunities for Equitable Pay.

Clinical journal of the American Society of Nephrology : CJASN·2022
Same journal

A Patient's Perspective on Arteriovenous Fistula Care and Far-Infrared Radiation Arteriovenous Fistula Therapy.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

A Beacon of Hope: Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Sequential Biomarker Testing in Kidney Transplant Surveillance: How Far Does One Step at a Time Take Us?

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

The Predicting Risk of Cardiovascular Disease Event Equation Meets CKD.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Muscle Cramp Rate, Severity and Burden in Maintenance Hemodialysis Patients: A Yearlong Multicenter Quality Improvement Initiative.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

From Risk Determinants to Clinical Action: Understanding and Implementing the Cardiovascular Kidney Metabolic Syndrome Framework.

Clinical journal of the American Society of Nephrology : CJASN·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.6K

Immunosuppressive Medications.

Alexander C Wiseman1

  • 1Division of Renal Diseases and Hypertension, Transplant Center, University of Colorado, Denver, Aurora, Colorado Alexander.wiseman@ucdenver.edu.

Clinical Journal of the American Society of Nephrology : CJASN
|July 15, 2015
PubMed
Summary
This summary is machine-generated.

Immunosuppressive agents are crucial for treating autoimmune diseases and transplantation. Advances in understanding immune responses have led to targeted therapies with improved outcomes for kidney diseases.

Keywords:
GNactivationcellcytokinesimmunologykidney transplantation

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.5K

Related Experiment Videos

Last Updated: Apr 7, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.6K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.5K

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Immunosuppressive agents are mainstays in nephrology for autoimmune diseases, transplantation, and investigational for acute kidney injury (AKI) and end-stage renal disease (ESRD).
  • Drug development accelerated due to improved understanding of immune response mechanisms, both serendipitous and mechanistic.
  • Early agents like corticosteroids, azathioprine, and cyclophosphamide had toxicities, driving the search for more specific and safer alternatives.

Purpose of the Study:

  • To provide a mechanistic context for immunosuppressive agents used in nephrology.
  • To discuss unique features of immunosuppressive drug development and application relevant to nephrologists.
  • To highlight advancements in immunosuppressive therapy for kidney diseases.

Main Methods:

  • Review of scientific literature on immunosuppressive agents.
  • Analysis of drug development pathways and their impact on immune response understanding.
  • Discussion of mechanistic contexts for therapeutic applications in nephrology.

Main Results:

  • Over 30 years, improved understanding of immune mechanisms has yielded numerous immunosuppressive options.
  • These agents have reduced rejection rates and improved graft survival in kidney transplantation.
  • New interventions are available for common (AKI) and rare (atypical hemolytic syndrome) kidney diseases.

Conclusions:

  • Mechanistic insights have significantly advanced immunosuppressive therapy in nephrology.
  • Current options offer improved efficacy and safety profiles compared to earlier agents.
  • Immunosuppressive agents present expanding opportunities for managing diverse kidney conditions.